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Adaptive immunity in both mouse and man results in the generation of immunological
memory. Memory T cells are both friend and foe to transplant recipients, as they are
intimately involved and in many cases absolutely required for the maintenance of protec-
tive immunity in the face immunosuppression, yet from the evidence presented herein
they clearly constitute a formidable barrier for the successful implementation of tolerance
induction strategies in transplantation. This review describes the experimental evidence
demonstrating the increased resistance of memory T cells to many distinct tolerance
induction strategies, and outlines recent advances in our knowledge of the ways in which
alloreactive memory T cells arise in previously untransplanted individuals. Understanding
the impact of alloreactive memory T cell speciﬁcity, frequency, and quality might allow
for better donor selection in order to minimize the donor-reactive memory T cell barrier in
an individual transplant recipient, thus allowing stratiﬁcation of relative risk of alloreactive
memory T cell mediated rejection, and conversely increase the likelihood of successful
establishment of tolerance. However, further research into the molecular and cellular path-
ways involved in alloreactive memoryT cell-mediated rejection is required in order to design
new strategies to overcome the memoryT cell barrier, without critically impairing protective
immunity.
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OVERVIEW OF MEMORY T CELL PROGRAMMING
One of the hallmark features of adaptive immunity is immuno-
logic memory. Antigen-speciﬁc T cells that have experienced a
prior encounter with cognate antigen exist at a higher precursor
frequency than they did as naïve clones, and have acquired a dif-
ferentiation program that allows them to rapidly and robustly
respond to subsequent encounters, usually at a lower activa-
tion threshold than their naïve counterparts (Ahmed and Gray,
1996). The last 20 years have seen an explosion in new knowledge
regarding the instructional developmental programs that impart
these qualities upon memory T cells, and most of this knowl-
edge has come from the study of memory T cell differentiation
in response to viral infection. It is now known that following
clonal expansion and contraction of an antigen-speciﬁc T cell
population, a heterogeneous memory pool consisting of central
and effector memory populations remains. Recently, studies have
focused on elucidating factors that identify short-lived effectors
and memory cell precursors at very early timepoints following
infection.
During the primary CD8+ T cell response to antigen, short-
lived effector cells fail to re-express CD127 and upregulate the
senescence marker KLRG-1 (Kaech et al., 2003; Huster et al., 2004;
Sarkar et al., 2008). Memory precursor cells upregulate CD127
and remain KLRG-1 low, although several studies have shown
that CD127 is permissive but not instructive or even required for
memory cell formation (Lacombe et al., 2005;Wojciechowski et al.,
2006;Hand et al., 2007).After the contraction phase,CD8+ central
memory cells are maintained in lymph tissues due to expression of
CD62L and CCR7, while effector memory cells have greater cyto-
toxic potential and reside in peripheral tissues (Sallusto et al., 1999;
Masopust et al., 2001). The transcription factorsT-bet, eomesoder-
min,Blimp-1, and the serine kinasemTORhave been implicated in
the distinct differentiation programs of long-lived CD8+ memory
precursors as compared to short-lived effector T cells (Intlekofer
et al., 2005, 2007; Joshi et al., 2007; Kallies et al., 2009; Rutishauser
et al., 2009; Shin et al., 2009; Banerjee et al., 2010). Speciﬁcally,
T-bet and BLIMP-1 are thought to be critical in the differentiation
and contraction of CD8+ effector T cell populations, as evidenced
by the increaseddifferentiationof memoryCD8+ Tcells in bothT-
bet−/− and BLIMP−/− animals (Intlekofer et al., 2005; Joshi et al.,
2007; Kallies et al., 2009; Rutishauser et al., 2009; Shin et al., 2009;
Welsh, 2009; Rao et al., 2010). In contrast, CD8+ T cells lacking
eomesodermin were shown to compete poorly in differentiating
into central memory cells (Araki et al., 2008; Banerjee et al., 2010;
Rao et al., 2010).More speciﬁcally, eomesodermin-deﬁcientCD8+
Tcells showed similarmagnitude andkinetics of expansion follow-
ing antigen priming as compared to wild-type T cells, but were less
able to survive long-term, were defective in establishing a mem-
ory pool in the bone marrow, and exhibited diminished secondary
recall responses (Banerjee et al., 2010). Taken together, these data
suggest that that T-bet and eomesodermin have reciprocal func-
tions in terms of their abilities to promote the differentiation of
short-lived effector cells versus long-lived memory precursor cells.
However, the molecular mechanisms underlying the regulation of
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these transcription factors is still largely unknown and is an area
of intense investigation.
CD4+ memory T cell programming has received comparably
less attention than CD8+ T cell memory, due in part to the fact
that CD4+ memory T cells exist at lower frequencies than CD8+
memory T cells (Harrington et al., 2008; Pepper et al., 2011), and
that class II tetramers for the detection of polyclonal endoge-
nous antigen-speciﬁc memory T cells have been developed only
recently (Landais et al., 2009). However, many features of CD4+
memory differentiation are emerging. Similar to the differentia-
tion of CD8+ memory T cells (Wherry et al., 2003; Wherry and
Ahmed, 2004), Th1 effector memory cells arise from Th1 effec-
tors during clonal expansion (Harrington et al., 2008; Lohning
et al., 2008; Sprent et al., 2008). While CD127 is also permissive
for CD4 memory cell formation, the transcription factors T-bet,
Blimp-1, and eomesodermin do not delineate memory CD4 cell
precursors in the same way as they do for CD8+ memory (Yang
et al., 2008; Pepper et al., 2010). However, a recent study revealed
that a subset of CD4+ cells that displayed decreased expression
of Ly6C and T-bet following antigen encounter were better able
to survive long-term and demonstrated superior recall responses
to secondary challenge (Marshall et al., 2011). The authors of this
study also compared the gene expression proﬁles of the population
of Ly6Clo T-betint CD4+ effector cells to that of mature memory
CD4+ T cells, and found them to be virtually identical. These data
suggest that Ly6Clo T-betint CD4+ cells comprise a population
of early maturating memory CD4+ within the pool of effectors.
In addition, two reports have shown that CD4+ central memory
cells have a T follicular helper-like CCR7+CXCR5+ phenotype
(Chevalier et al., 2011; Pepper et al., 2011). It is these molecular
changes that in part are responsible for memory T cells’ supe-
rior functional capabilities, long life span, and reduced activation
requirements upon recall as compared to their naïve counterparts
(Sallusto et al., 1999).
EVIDENCE FOR ALLOREACTIVITY AMONG MEMORY
When examining the potential barrier posed by alloreactive mem-
ory T cells, one must ﬁrst consider the evidence that alloreactivity
exists within the memory T cell compartments of mouse and
man. For at least the last two decades, there has been consid-
erable debate concerning the relative precursor frequencies of
alloreactive clones among naïve vs. memory T cell populations
(Lombardi et al., 1990; Lechler et al., 1991). This question was ﬁrst
addressed by seminal studies which approached the problem by
using cord blood-derived T cell preparations, which were shown
to contain little to no memory T cells (Lombardi et al., 1990), and
later by ELISPOT techniques to identify cells secreting cytokines in
response to brief stimulationwith alloantigen (Heeger et al., 1999).
Because naïve T cells do not begin to produce cytokines until 16–
24 h post stimulation, these early cytokine producers were deemed
alloreactive memory T cells. However, our ability to probe these
questions has matured along with the evolution of our under-
standing and identiﬁcation of memory T cell phenotypes and
ability to physically sort these subsets using ﬂow cytometry. Specif-
ically, a 2009 studywhich analyzed the frequencies of alloreactive T
cells in naïve (CD45RO− CD62L+), central memory (CD45RO+
CD62L+), effector memory (CD45RO+ CD62L−), and terminal
effector memory (CD4RO− CD62L−) compartments addressed
this issue, and revealed that approximately equal frequencies of
alloreactive T cells exist among these subsets (Macedo et al., 2009).
Perhaps one reason that the frequency of alloreactivity among
memory T cell compartments has been debated lies in the fact
that there are differences in the ways in alloreactivity manifests
in naïve vs. memory T cell compartments. In particular, Macedo
et al. (2009) found that when proliferation was used as a read-out,
it appeared as though there was a higher precursor frequency of
alloreactive T cells among naïve as compared to memory CD8+
T cells. However, when perforin/granzyme expression was used
as a read-out, it appeared as though there was a higher precursor
frequency of alloreactive T cells among TEM as compared to naïve
CD8+ T cells (Macedo et al., 2009). It should therefore be noted
that even though the frequencies of alloreactive T cell clones might
be comparable between naïve and memory T cell compartments,
the immunological manifestation of recognition of alloantigen
might be very different, with potential profound impacts on graft
acceptance vs. rejection.
HOW ARE ALLOREACTIVE MEMORY T CELLS GENERATED?
Thegenerationof donor-reactivememoryTcells can arise through
multiple independent mechanisms (Figure 1), and it is likely that
many if not all of the thesemechanisms are at playwithin themem-
ory T cell compartment of a given individual. The generation of
donor-reactive memory T cells can be subdivided into three main
categories: (1) generation of “traditional” donor-reactive memory
T cells following sensitization with alloantigen, (2) the genera-
tion of memory through antigen-independent mechanisms, and
(3) the generation of allo-cross-reactive memory T cells follow-
ing exposure to non-alloantigens. First, donor-reactive memory
T cells can certainly arise from prior sensitization with allogeneic
tissue. Reports from both experimental models (Valujskikh et al.,
2002; Zhai et al., 2002) and clinical patients (Heeger et al., 1999)
revealed worse outcomes in recipients of a prior graft, consis-
tent with “second set” rejection (Figure 1). Alloreactive memory
T cells can also arise during pregnancy, during which time the
female can be primed against paternal antigens carried by the
fetus (van Halteren et al., 2009). Furthermore, a recent study also
found that immunity generated following platelet transfusion was
sufﬁcient to induce rejection following a subsequent bone mar-
row transplantation in murine recipients, even across only minor
histocompatibility antigens (Patel et al., 2009). Since platelet trans-
fusion is a common occurrence prior to liver transplantation in
particular, these data indicate that the subpopulation of highly
tranfused transplant recipients may be at an increased risk for
memory T cell-mediated graft rejection.
Second, alloreactive memory T cells may be generated in an
antigen-independent manner when in a lymphopenic environ-
ment exists in the host. In these instances, naïve CD4+ and CD8+
alloreactive precursors are induced to undergo IL-7-dependent
homeostatic proliferation and differentiation into memory T
cells (Goldrath et al., 2000; Murali-Krishna and Ahmed, 2000;
Figure 1). Seminal studies from Turka and colleagues showed that
both adoptive transfer of lymphocytes into T and B-cell devoid
SCID recipients and experimental depletion of lymphocytes in
murine transplant recipients resulted in rapid reconstitution of
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FIGURE 1 | Generation of donor-reactive memoryT cells. An alloreactive
memoryT cell pool may be generated through at least four different pathways.
(A)Traditional donor-reactive memory may form following sensitization with
alloantigen presented by donor or recipient antigen-presenting cells. (B)
Pathogen-derived antigen, such as viral antigens, may elicit T cell memory that
is cross-reactive with alloantigen. (C) Dual-receptor T cells may be activated
by non-allogeneic antigen, creating memory populations that are alloreactive
through the secondT cell receptor. (D) Lymphopenia induced by
pharmacological treatment or infection may induce antigen-independent
homeostatic proliferation and generate alloreactive memory T cells. Light blue
and greenT cells represent naïve T cells. Clonally expandingT cell populations
contain combinations of pathogen-reactive (green) and alloreactive (blue)
cells. Memory populations also contain pathogen-reactive and alloreactive T
cells. Ag, antigen. DC, dendritic cell.
peripheral T cell compartments with memory T cells (Wu et al.,
2004). These ﬁndings may be clinically relevant in that lymphope-
nia can be induced in patients following infection with a viral
pathogen such as HIV, or following therapeutic depletion of T
cells for the treatment of autoimmunity or transplantation, and
residual naïve T cells might be induced to undergo rapid divi-
sion and acquisition of a memory-like phenotype (Sener et al.,
2009). Studies from non-transplant models have revealed that
these“pseudomemory”T cells have functional characteristics sim-
ilar to those of memory T cells as well (Goldrath et al., 2000;
Murali-Krishna and Ahmed, 2000). Thus, lymphopenia-induced
immunologic memory seems to be both as phenotypically and
functionally competent as true antigen-dependentmemory.Mem-
ory cells generated in this manner have also been shown to consti-
tute a barrier to tolerance induction, discussed more below (Wu
et al., 2004).
A third and often-overlooked mechanism by which donor-
reactive memory T cells might be generated is through the acti-
vation of dual-receptor T cells (Figure 1). Although most T cells
express a single alpha and beta chain by virtue of the principle of
allelic exclusion of T cell receptor (TCR) genes, the existence of
T cells expressing either two alpha or two beta chains has been
documented. Indeed, Lanzavecchia’s laboratory showed that up to
30% of human T cells express a second alpha chain at the mRNA
level and 8% expressed one at the protein level (Padovan et al.,
1993). Thus, one could envision a situation in which two dis-
tinct TCRs, one speciﬁc for an alloantigen and one speciﬁc for a
pathogen, could co-exist on the same T cell. If that T cell encoun-
ters the pathogen-derived antigen for which it is speciﬁc, it could
become activated and differentiate into a memory T cell. If that
same T cell were at some future time to encounter its cognate
alloantigen, it would respond as memory T cell despite never have
seen that antigen before. What is the evidence that dual-receptor
alloreactive T cells exist and can participate in graft rejection? A
recent study by Allen’s group showed that dual-receptor CD4+
T cells were enriched in the alloreactive T cell compartment in
a murine model of graft-versus-host disease (Morris and Allen,
2009). However, the contribution of dual-receptor T cells to rejec-
tion of solid organs and in human patients warrants further
investigation.
www.frontiersin.org March 2012 | Volume 3 | Article 36 | 3
Krummey and Ford MemoryT cells in transplantation
TCR CROSS-REACTIVITY AND THE GENERATION OF
ALLOREACTIVE MEMORY
In addition to the mechanisms discussed above, studies in both
mouse and human have revealed that alloreactive memory T cells
can in fact be generated by prior exposure to pathogens (Pan-
tenburg et al., 2002; Adams et al., 2003; Brehm et al., 2003).
This can occur through a process termed heterologous immu-
nity (Pantenburg et al., 2002; Adams et al., 2003; Brehm et al.,
2003), whereby TCRs present on virus-speciﬁc memory T cells
cross-react with alloantigen (Figure 1). This phenomenon is based
upon the intrinsic cross-reactivity of most TCRs to a wide spec-
trum of related peptide:MHC ligands, deﬁned in early seminal
studies wherein amino acid substitutions at TCR contact residues
within the original antigenic ligand revealed that individual TCRs
responded to a spectrum of peptides with unrelated or minimally
related sequences, and that stimulation with these peptides could
evoke differential quantity and quality of responses from the T cell
(Evavold et al., 1993; Sloan-Lancaster and Allen, 1996; Ford and
Evavold, 2004). Interestingly, it has been estimated that a single
TCR may be capable of recognizing up to 106 distinct ligands, and
computational analysis of the T cell repertoire suggested that this
high degree of TCR cross-reactivity is in fact required for complete
coverage of the multitude of potential peptide epitopes that could
be generated by pathogens (Nikolich-Zugich et al., 2004). The
implications of this intrinsic cross-reactivity support the concept
of heterologous immunity, suggesting that microbial pathogens
might activate antigen-speciﬁc T cells that then cross-react with
allogeneic tissue and result in graft rejection. Experimental evi-
dence that such cross-reactivity between pathogen-derived and
graft-derived epitopes includes seminal studies by Burrows et al.
(1994, 1995, 1997) demonstrating that CD8+ T cells speciﬁc
for EBV-EBNA3A restricted by HLA-B8 were cross-reactive with
HLA-B44 presenting a self-peptide with a sequence unrelated to
the EBNA3A epitope. This self-peptide displays a restricted pat-
tern of expression, a ﬁnding which has important implications for
the tissue-speciﬁcity of alloimmunity (D’Orsogna et al., 2011a).
Other examples of documented cross-reactivity between viral and
alloepitopes include evidence that CD4+ T cells-speciﬁc for a
tetanus toxoid peptide presented in the context of HLA-DR3 were
cross-reactive with HLA-DR4 (Umetsu et al., 1985), and a T cell
speciﬁc for HSV-VP13/14 in the context of A2 has been shown
to cross-react with HLA-B44 (Koelle et al., 2002). While early
studies documented the existence of cross-reactivity in these set-
tings, they failed to rule out bystander activation as a potential
explanation for the observed results. More recently, however, new
experimental evidence has emerged identifying true molecular
mimicry as a potential explanation for the observed alloreactiv-
ity within heterologous immune responses. Most prominently, in
a recent seminal study interrogating the speciﬁcity of alloreac-
tive CD4+ T cells for peptide:MHC complexes, Felix et al. found
that alloreactive T cells have the inherent propensity to respond
to multiple, distinct peptide epitopes that did not share sequence
homology (Felix et al., 2007). The same ﬁnding was also observed
in CD8+ human T cell clones, in that when syngeneic human T
cell populations were primed with a speciﬁc tumor antigen, the
responding T cell clones were highly speciﬁc for the immunizing
antigen, as would be expected (Falkenburg et al., 2011). However,
in surprising contrast, when allogeneic T cell populations were
primed with the same tumor antigen, the responding CD8+ T
cell clones were speciﬁc for not only the immunizing antigen,
but a wide range of both related and unrelated peptide epitopes
(Falkenburg et al., 2011). Taken together, these data demonstrated
that alloreactive T cells are more “poly-speciﬁc” as compared to
conventional T cells and thus may possess the ability to recognize
many unrelated peptide sequences (Felix and Allen, 2007). The
concept of the “poly-speciﬁcity” of alloreactive T cells was further
conﬁrmed by the results of McCluskey et al. who interrogated the
molecular mechanisms underlying the observed cross-reactivity
of EBV-EBNA3A/HLA-B08 restricted TCR with HLA-B44 mol-
ecules (Macdonald et al., 2009). Using a crystal structure-based
approach, their ﬁndings suggested that the binding modes of a
single TCR to two distinct, unrelated cognate and allogeneic pep-
tide:MHC complexes were virtually identical. Interestingly, these
data also supported an induced-ﬁt model of TCR recognition
of alloepitopes, since it was only following TCR ligation that
the viral and allopeptides acquired the same conformation (Bed-
doe et al., 2009; Macdonald et al., 2009). Taken together, these
recent advances have therefore deﬁnitively demonstrated that het-
erologous immunity between pathogen-derived and transplant
antigens can function at the level of molecular mimicry, facili-
tated in part by the intrinsic promiscuity of alloreactive T cell
clones.
While these examples conﬁrmed the existence of molecular
mimicry as amechanismunderlying heterologous immunity, until
very recently the experimental evidence for the existence of virally
elicited allo-cross-reactive memory T cells was based on examples
of speciﬁc donor-recipient pairs eliciting cross-reactivity between
pathogen-elicited memory T cells and alloepitopes, but lacked a
systematic evaluation of the prevalence of this phenomenon. A
study by Amir et al. (2010) suggested that heterologous immu-
nity is not limited to a few anecdotal instances, but in fact is
quite common. Using MHC tetramers for FACS-purify pathogen-
speciﬁc T cell lines and clones, the authors tested the reactivity
of these cells against a panel of HLA-typed target cells. Strik-
ingly, they observed that fully 80% of CD8+ T cell lines and 45%
of pathogen-speciﬁc CD8+ T cell clones exhibited alloreactivity
against at least one MHC allele (Amir et al., 2010). Subsequent
experiments utilizing a TCR gene transfer approach conﬁrmed
that both the pathogen- and alloreactivity could be conferred by a
single TCR, thus demonstrating true TCR cross-reactivity and rul-
ing out the involvement of dual-receptor T cells in these instances
(Amir et al., 2010). The potential for pathogen-induced allore-
active T cell responses to manifest clinically were highlighted in
a recent case report study in which a de novo alloreactive T cell
response was generated following varicella-zoster vaccination in
an individual awaiting renal transplantation (D’Orsogna et al.,
2011b). In sum, these recent studies demonstrating that pathogen-
elicited allo-cross-reactive T cell memory is perhaps much more
common than originally anticipated may have important impli-
cations for the ﬁeld of transplantation (D’Orsogna et al., 2010).
Speciﬁcally, if a large proportion of memory T cell clones possess
intrinsic alloreactivity, and a given patient possesses tens of mil-
lions of memory T cell clones, the relevant question is not simply
if donor-reactive memory T cells exist in any given individual, but
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rather the extent to which they exist, and to assess whether their
frequency, phenotype, and functionality results in a signiﬁcant
barrier to tolerance or even long-term graft survival.
ALLOREACTIVE T CELL MEMORY IS HIGHLY DONOR-SPECIFIC
Despite intrinsic cross-reactive potential of TCRs, studies of virus-
speciﬁc human memory T cell clones revealed that while allo-
cross-reactivity was indeed very common, this cross-reactivity was
usually conﬁned to a single HLA molecule (Amir et al., 2010).
Thus, while several studies have now shown that that alloreac-
tivity exists among memory, the extent to which donor-reactive
memory T cells are present appears to be highly dependent on
the donor tissue tested. This is an important ﬁnding because it
had previously been hypothesized that due to the lower activation
threshold of memory T cells, many different alloantigens might
be capable of stimulating memory T cells. In a 2007 study, Beni-
chou and coworkers stimulated CD8+ memory T cells from 11
different non-human primates with a panel of 14 different stimu-
lator cells, and found that the donor-reactive CD8+ memory T cell
precursor frequencies within a given individual spanned an over
40-fold range depending on the allostimulator used (Nadazdin
et al., 2010). Interestingly, the authors also reported that naïve
alloreactive T cell precursor frequencies did not range as widely
across the different responder: stimulator pairs tested, suggest-
ing that the observed difference in donor-reactive memory T cell
precursor frequencies was not due to intrinsic differences in the
alloreactive T cell repertoires of these animals, but instead was
likely due to differences in their immunologic histories (Nadazdin
et al., 2010).
BYSTANDER ACTIVATION: PATHOGEN-SPECIFIC RESPONSES
THAT INFLUENCE ALLOREACTIVITY IN AN
ANTIGEN-INDEPENDENT MANNER
The above studies deﬁnitively demonstrate that TCR cross-
reactivity is an important mechanism by which pathogen infec-
tion can result in alloimmunity and therefore pose a barrier to
long-term graft survival. However, it is critical to note that non-
speciﬁc so-called bystander activation also plays an important
role in the pathogen-mediated barrier to allograft acceptance.
Indeed, studies in murine models of infection prior to and/or
following transplantation have demonstrated that both the type
of infection and timing relative to transplantation can inﬂu-
ence the impact of infections on alloimmunity. In particular,
previous reports have shown that simultaneous infection of a
murine transplant recipient with LCMV Armstrong or with Liste-
ria monocytogenes can increase alloreactivity, accelerating rejec-
tion and potentially abrogating tolerance induction (Williams
et al., 2001; Wang et al., 2008). However, similar studies showed
that infection with LCMV Armstrong after tolerance was already
established did not impact graft survival (Williams et al., 2001),
and infection with LCMV Armstrong prior to transplantation
abrogated tolerance induction in only 7% of mice (Williams
et al., 2002). In contrast, prior infection of transplant recipi-
ents with LCMV clone 13, which persists for the life of the
host, completely inhibited tolerance induction in 100% of the
recipients (Williams et al., 2002). Furthermore, established tol-
erance in murine models can be broken by subsequent infection
with Listeria but not Staphylococcus aureus (Wang et al., 2010).
Overall, these ﬁndings indicate that the inﬂammatory milieu of
a particular viral or bacterial infection can impact the priming
and/or recall of alloimmune responses (Ahmed et al., 2011a).
The mechanisms underlying this phenomenon involve the abil-
ity of a particular infectious agent to induce the adjuvant effects
of IL-6 and type I interferons (Wang et al., 2010; Ahmed et al.,
2011b), and also likely the ability of pathogen infections to
license dendritic cells that may also be presenting alloepitopes
(Alegre et al., 2008a,b), either through the direct or indirect
pathway.
The tropism of the viral pathogen is also likely to play a role in
determining its impact on alloreactive T cell responses and ulti-
mately on tolerance induction. For example, if the virus infects
the transplanted organ, as in the case of hepatitis C virus or BK
virus, viral-speciﬁc T cells may play a greater role in mediating
bystander activation of alloreactive T cells and thus inhibiting
tolerance induction. This phenomenon was demonstrated exper-
imentally following infection of murine renal allograft recipients
with mouse polyoma virus, a relative of human BK virus that
infects the kidney, revealing that polyoma virus infection resulted
in acute rejection of allogeneic but not syngeneic transplanted
kidneys (Han Lee et al., 2006). The authors also demonstrated a
concomitant increase in alloantigen-speciﬁc CD8+ T cells by ﬂow
cytometry (Han Lee et al., 2006). Subsequent studies have failed
to detect TCR cross-reactivity of viral-speciﬁc T cells with alloepi-
topes, suggesting instead that the increased inﬂammatory milieu
generated by the viral infection in the kidney increased the acti-
vation and differentiation of the alloreactive T cell clones in an
antigen-independent manner.
MEMORY T CELLS POSE A BARRIER TO TOLERANCE
INDUCTION
As discussed above, memory T cells are distinct from their naïve
counterparts with regards to both phenotype and function, pos-
sessing both a lower activation threshold and ability to respond
rapidly upon restimulation (Lanzavecchia and Sallusto, 2000a,b).
Memory T cells are also hallmarked by their reduced requirement
for both TCR stimulation (signal one) and costimulatory signals
(signal two) for recall responses (Lanzavecchia and Sallusto,2000b;
London et al., 2000). In addition, memory cells express higher
levels of adhesion molecules such as LFA-1, VLA-4, and CD44,
cytokine receptors such asCD122 and IL-15Rα, and anti-apoptotic
molecules of the Bcl-2 family relative to naïve T cells (Zhang et al.,
1998; Grayson et al., 2000, 2001). They also possess altered lev-
els of transcription factors T-bet, eomesodermin, and Blimp-1 as
compared to naïve or effector T cells. Due in large part to these
changes, donor-reactive memory T cells are therefore relatively
refractory to several distinct therapeutic interventions with unre-
lated mechanisms of action. First, results from analysis of human
samples reveals thatmemoryT cells aremore resistant to even con-
ventional immunosuppression, as transplant recipients bearing a
higher frequency of pre-transplant IFN-γ-producing memory T
cells exhibited poorer graft outcomes following treatment with a
standard calcineurin inhibitor-based regimen (Heeger et al., 1999).
Furthermore, perhaps the most well-studied of example of the
memory T cell barrier is the observed resistance of donor-speciﬁc
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memory T cells, elicited either by exposure to donor antigens
or viral pathogens, to tolerance induction via CD40 and CD28
costimulation blockers (Pantenburg et al., 2002; Valujskikh et al.,
2002; Zhai et al., 2002; Adams et al., 2003). In contrast, numerous
studies have demonstrated that blockade of these costimulatory
pathways during transplantation are highly effective in tolerizing
naïve donor-reactive T cells and lead to prolonged graft sur-
vival in both murine and non-human primate models (Linsley
et al., 1992; Larsen et al., 1996; Kirk et al., 1997). Importantly,
the costimulatory requirements of donor-reactive memory T cells
during transplantation are particularly relevant in that reagents
designed to block CD28 costimulatory molecules were recently
FDA approved for the prevention of graft rejection (Vincenti
et al., 2005, 2010; Durrbach et al., 2010). This observed costimu-
lation independence of donor-reactive memory T cells in models
of transplantation may have been predicted from basic in vitro
analyses of T cell function demonstrating that memory T cells
could become fully activated following in vitro stimulation with
B7-deﬁcient APC (Croft et al., 1994; Bachmann et al., 1999; Kim
et al., 1999; London et al., 2000), and the ﬁnding that CD28−/−
mice do not exhibit a gross impairment in their ability to gener-
ate memory T cells in response to LCMV infection, or for these
memory T cells to respond upon secondary rechallenge (Suresh
et al., 2001). In transplant models, a seminal study examining the
pathogen-elicited memory barrier revealed that while CD28 and
CD154 costimulation blockade effectively inhibited graft rejec-
tion in naïve recipients, animals that had previously been infected
with one, two, or three different viruses were relatively refrac-
tory to the tolerance-inducing effects of costimulation blockade
(Adams et al., 2003). While this study focused primarily on the
CD8+ memory T cell barrier, it is clear that both CD4+ and CD8+
donor-speciﬁc memory cells can constitute a barrier to costimula-
tion blockade-induced tolerance (Adams et al., 2003; Chen et al.,
2004). For example, similar studies showed that mice infected with
Leishmania major exhibited increased resistance to costimulation
blockade-induced acceptance of fully MHC disparate allografts,
and attributed this resistance to allo-cross-reactive CD4+ T cells
primed by Leishmania infection (Pantenburg et al., 2002). In
addition, approaches that utilized total body irradiation or non-
myeloablative conditioning in combination with costimulatory
blockade to induce mixed hematopoietic chimerism in recipient
animals were highly efﬁcacious at inducing tolerance in naïve lab-
oratory mice (Sykes and Sachs, 1988; Sykes et al., 1997; Durham
et al., 2000; Adams et al., 2001; Sykes, 2001), but met with less
uniform success in the translation of this strategy to non-human
primates (Kawai et al., 1995, 1999a,b, 2001a,b, 2004; Kean et al.,
2007), which, among other challenges, have much higher frequen-
cies of memory T cells in their peripheral blood than laboratory
mice housed in speciﬁc pathogen free conditions (Kean et al.,
2006; Ochiai et al., 2007). Importantly, a recent study examining
the efﬁcacy of combined costimulatory blockade/bone marrow
or donor-speciﬁc transfusion (DST)-based based approach to
induce tolerance in non-human primate recipients of renal trans-
plants showed that higher pre-transplant precursor frequencies of
donor-reactive memory T cells (as measured by ELISPOT) cor-
related with failure of tolerance induction and acute rejection of
the grafts, while low pre-transplant donor-reactive memory T cell
frequencies portended successful tolerance induction and long-
term renal allograft survival (Ford and Larsen, 2011; Nadazdin
et al., 2011). In support of these ﬁndings, a similar study used
the same costimulatory blockade/DST based strategy to attempt
to induce tolerance to a previously transplanted kidney (Koyama
et al., 2007). Their results showed that this regimen, while success-
ful at inducing tolerance when the DST and renal allograft were
transplanted simultaneously, failed in the case where the donor
was essentially pre-sensitized due to prior transplantation of the
renal allograft. The authors of this study showed that memory T
cells were refractory to the tolerance induction regimen and there-
fore were likely responsible for the failure of the establishment of
tolerance in these recipients (Koyama et al., 2007).
In addition to their resistance to costimulation blockade and
chimerism based therapies, memory T cells demonstrate a rela-
tive resistance to antibody-mediated depletion using both anti-
lymphocyte serum (ALS) in mice (Minamimura et al., 2008) or
alemtuzumab (Campath-1H) in humans (Pearl et al., 2005). These
memory T cells that can persist following treatment with deple-
tional therapy are also poised to undergo homeostatic expansion
and repopulate the host during reconstitution (Pearl et al., 2005).
The mechanisms underlying the relative resistance of memory T
cells to antibody-mediated depletion are not well understood. The
increased expression of anti-apoptotic molecules such as Bcl-2
family members may be responsible for the observed increased
resistance to death, however, an alternative hypothesis is that
monoclonal antibodies or other therapeutics present at high con-
centrations in the bloodstream may not necessarily achieve these
high concentrations in peripheral tissues, which are sites to which
effector memory T cells home (Woodland and Kohlmeier, 2009).
Understanding the ability of monoclonal antibodies to target tis-
sue resident memory T cells remains an important area of future
investigation.
Lastly,memoryTcells have alsobeen shown to exhibit increased
resistance to regulation by CD4+ CD25+ FoxP3 regulatory T
cells (Treg). This observation was ﬁrst made in a murine adoptive
transfer model, wherein transferred CD4+ CD25+ cells effectively
inhibited the rejection mediated by naïve but not memory CD4+
T cells (Yang et al., 2007). Regulatory T cells were similarly found
unable to regulate CD8+ alloreactive T cell responses. Interest-
ingly, this was true for both naïve Treg and alloantigen “primed”
Treg, suggesting that strategies to enhance the frequency and/or
activation of alloantigen-speciﬁc FoxP3+ Treg are unlikely to be
effective against donor-reactive memory T cells (Li and Turka,
2010). A subsequent study revealed a similar resistance of human
alloreactive memory T cells to regulation by traditional CD4+
CD25+ FoxP3+ Treg (Afzali et al., 2011). However, a more recent
report suggested that in vitro stimulation of human T cells with
TLR-stimulated plasmacytoid dendritic cells resulted in the gener-
ation of CD8+ FoxP3+ LAG-3+ CTLA-4+ regulatory T cells that
were effective at inhibiting alloreactive memory T cell responses
(Boor et al., 2011).
HETEROGENEITY WITHIN THE MEMORY T CELL
COMPARTMENT
The last 20 years have witnessed major advances in our under-
standing of the generation, maintenance, and function of T cell
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memory. This work has led to the understanding that memory T
cells are do not constitute a homogenous population but rather
exhibit a wide array of phenotypes, functional properties, and
trafﬁcking patterns that render them likely to play discrete roles
in protective immune responses. Memory CD4+ and CD8+ T
cells are often segregated into two subsets, central (TCM) and
effector (TEM) memory (Sallusto et al., 1999), which even still
is likely a gross oversimpliﬁcation of the range of diversity con-
tained within the memory T cell compartment. TCM express the
lymph node homing receptors CD62L and CCR7, whereas TEM
lack these markers and instead express other adhesion molecules
and chemokine receptors which allow them to access peripheral
tissues (Wherry et al., 2003; Sallusto et al., 2004). In addition,
TCM and TEM differ in terms of their capacity for re-expansion
upon recall, in that TCM have high proliferative potential, express
CD27, elaborate IL-2 upon following re-encounter with antigen
(Wherry et al., 2003). Conversely, TEM possess lower proliferative
potential and reside primarily in non-lymphoid tissues, making
them poorly suited to mount secondary re-expansion of antigen-
speciﬁc T cell populations (Wherry et al., 2003). However, these
memory T cells likely constitute a ﬁrst line of defense, in that
they are immediately cytolytic upon Ag re-exposure, and rapidly
secrete inﬂammatory cytokines such as IFN-γ and TNF (Hislop
et al., 2001; Wherry et al., 2003; Bouneaud et al., 2005; Marzo
et al., 2005; Roberts et al., 2005). Speciﬁcally, recent work from
Fairchild’s laboratory demonstrated that memory T cells have the
potential to inﬁltrate allografts within 12–24 h, and showed that
this very early inﬁltration was antigen-independent (Schenk et al.,
2008). It is likely that the route of exposure, dose, replication
rate, and tropism of the infectious challenge all play important
roles in determining the relative proportion of each memory T
cell subset persisting after infection, and also the degree to which
each subset participates in protective immunity upon rechallenge
(Masopust et al., 2006). For example,Oberbarnscheidt et al. (2008)
showed in a study that CD8+ TCM and TEM rejected allografts
with equivalent kinetics in wild-type hosts. However, in animals
lacking secondary lymphoid organs, CD8+ TEM were signiﬁcantly
better than TCM at inducing rejection (Oberbarnscheidt et al.,
2008). With regard to heterogeneity in effector function, previous
work in models of pathogen-speciﬁc immunity and vaccination
demonstrated that multi-cytokine producing memory cells exhib-
ited superior protective function following secondary challenge
with antigen (Seder et al., 2008). A 2009 study from Kirk and col-
leagues revealed that this is likely also true for alloreactive memory
T cells, in that CD2hi multi-cytokine producing TEM were asso-
ciated with break-through rejection responses in a non-human
primate model of renal transplantation (Weaver et al., 2009). In
addition, these CD2hi multi-cytokine producing TEM expressed
the cytolytic effectormolecule granzymeB and underwent degran-
ulation in vitro (Weaver et al., 2009). Similar ﬁndings were also
true in studies of human alloreactive memory T cell responses (Lo
et al., 2011). Thus, this increased effectiveness in mediating graft
rejection may be linked to the ability to carry out a wide range of
effector functions, each of which has the potential to contribute to
graft destruction. Taken together, these data highlight the distinct
roles of individual memory T cell subsets in mediating allograft
rejection.
COSTIMULATION-INDEPENDENT RECALL RESPONSES: NOT
ALL MEMORY IS CREATED EQUALLY
This new understanding that memory T cells actually encom-
passes a wide spectrum of cellular phenotypes, functionalities, and
trafﬁcking patterns, suggests that despite the current dogma that
memory T cells do not require CD28/B7 and/or CD154/CD40
signals for recall responses, memory T cells may in fact exhibit a
range of requirements for costimulation during recall. In particu-
lar, the ﬁnding that blockade of CD28 can ameliorate established
autoimmunity in murine models of multiple sclerosis and type
1 diabetes suggest that memory T cells existing in these mod-
els could be inhibited following blockade of the CD28 pathway
(Khoury et al., 1995). Furthermore, administration of abata-
cept (CTLA-4 Ig) to human patients results in the amelioration
of both psoriasis and rheumatoid arthritis, both diseases medi-
ated by memory T cells against self antigens (Abrams et al.,
1999; Kremer et al., 2003; Bluestone et al., 2006). Importantly,
a recent study by Katsikis et al. found that CD8+ memory T
cells derived from adoptively transferred cells required CD28-
mediated costimulation for optimal recall responses in a model
of bacterial infection (Borowski et al., 2007). Taken together,
these ﬁndings suggest that under certain circumstances, mem-
ory T cells may depend on CD28 and/or CD154 mediated
costimulation in order to generate optimum secondary recall
responses.
The concept that memory T cells are not uniform in their
costimulation blockade resistance has been demonstrated in trans-
plant models as well. First, several studies have demonstrated
that CD4+ memory cells as a whole exhibit increased suscep-
tibility to CD28/CD154 costimulation blockade during recall as
compared with CD8+ memory T cells (Adams et al., 2003; Nde-
jembi et al., 2006). In addition, there is evidence from adoptive
transfer experiments in fully allogeneic experimental models that
TCM elicited via prior sensitization with BALB/c antigen posed
a greater barrier to costimulation blockade-induced tolerance as
compared with TEM (Adams et al., 2003). However, in a model of
allo-speciﬁc heterologous immunity following latent viral infec-
tion with a murine EBV homolog, TEM as opposed to TCM were
the culprits in terms of forming a barrier to tolerance induction
(Stapler et al., 2008). In studies of human transplant recipients,
TEM (and not as much TCM) have been implicated as posing a
relative barrier to the effects of therapeutic lymphocyte depletion
via either anti-thymocyte globulin or Campath-H1 (Pearl et al.,
2005).
In a recent study, we sought to determine the priming
conditions that inﬂuenced the programming of costimulation-
independent donor-reactive memory T cells. Previous work in
models of viral infection revealed that the amount/duration of
antigen exposure profoundly impacted the programmed differ-
entiation of memory T cells into short-lived effectors vs. long-
lived memory precursors, and inﬂuenced the phenotype and
functionality of the resulting memory T cell population (Sarkar
et al., 1975; Blair and Lefrancois, 2007; Kalia et al., 2008).
We interrogated the effect of differential duration of antigen
exposure during the initial priming phase of the response on
the programming of costimulation-independent donor-reactive
memory T cells during recall (Floyd et al., 2011). This series
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of experiments made use of a system in which OVA-speciﬁc
TCR transgenic T cells were primed by OVA-expressing Lis-
teria, resulting in the generation of pathogen-elicited donor-
reactive memory T cells. In order to limit the duration of
antigen exposure of donor-reactive cells during priming, recip-
ients were treated with ampicillin post-infection. These recip-
ients were subsequently transplanted with an OVA-expressing
skin graft to induce a secondary recall response in the presence
or absence of CD28 and CD154/CD40 costimulation blockade.
Results of these studies revealed that skin graft recipients bear-
ing donor-reactive memory T cell responses which had been
elicited under conditions of reduced antigen exposure exhib-
ited similar frequencies and phenotypes of antigen-speciﬁc T
cells as compared with non-ampicillin-treated controls (Floyd
et al., 2011). However, these donor-reactive T cells were unable
to mediate costimulation blockade-resistant rejection of the
OVA-expressing skin graft, indicating that the amount/duration
of antigen exposure is a critical factor in determining mem-
ory T cells’ relative requirement for CD28/CD154 costimula-
tion in the generation of a functional recall response following
transplantation.
MOUNTAIN OR MOLEHILL? POTENTIAL STRATEGIES TO
OVERCOME THE MEMORY BARRIER
Pre-existing donor-reactive memory T cells are likely to be a foe of
long-term allograft survival no matter which immunosuppressive
strategy is employed (Figure 2). For instance, studies assessing
the pre-transplant frequency of donor-reactive memory T cells
have identiﬁed a direct correlation between donor-reactive mem-
ory T cell precursor frequency (measured by IFN-γ production
following short ex vivo restimulation) and increased risk of acute
rejection while on standard calcineurin inhibitor-based immuno-
suppression (Heeger et al., 1999). However, direct assessment of
the impact of calcineurin inhibition on alloreactive memory T cell
responses revealed a strong inhibition of alloreactive T cell prolif-
eration (Pearl et al., 2005).While calcineurin inhibition may effec-
tively attenuate memory T cell recall responses, it is also associated
with a number of off-target toxicities that lead to the development
of hyperlipidemia, type II diabetes, cardiovascular events, and, not
insigniﬁcantly, renal failure (Halloran, 2004). Identiﬁcation and
therapeutic targeting of those pathways critical for the initiation
and maintenance of donor-reactive memory T cells is an impor-
tant area of investigation in the ﬁeld. As discussed above, work in
FIGURE 2 | Major therapeutic targets for inhibition of donor-reactive
memoryT cell responses.Transplantation therapeutics have been developed
that target memory T cell costimulation pathways, intracellular signaling
pathways, and trafﬁcking molecules. Alemtuzumab, anti-CD52 monoclonal
antibody. Alefacept, LFA-3 Ig fusion protein. Belatacept, high-afﬁnity CTLA-4
Ig fusion protein. Anti-OX40L mAb, anti-OX40 ligand monoclonal antibody.
Efalizumab, anti-LFA-1 monoclonal antibody. Natalizumab, anti-VLA-4
monoclonal antibody. Sirolimus, Mammalian Target of Rapamycin (mTOR)
pathway inhibitor. Tacrolimus, Calcineurin A (CnA)-NFAT pathway inhibitor.
Oxelumab, anti-OX40 monoclonal antibody. Bortezomib, protease inhibitor.
Gray box, FDA approved therapeutic. Blue box, experimental therapeutic
under clinical development.
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animal models has revealed that memory T cells are for the most
part not effectively inhibited by CD28 costimulation blockade.
This increased resistance may in part explain the increased inci-
dence and severity of acute rejection episodes observed in patients
treated with the CD28 blocker belatacept (Larsen et al., 2005),
as compared to cyclosporine-treated controls in recent Phase II
and Phase II studies of renal transplant recipients (Vincenti et al.,
2005, 2010; Durrbach et al., 2010). Determining whether high
pre-transplant donor-reactive memory T cell precursor frequency
actually correlates with increased incidence and severity of acute
rejection in human renal allograft recipients treated with belata-
cept constitutes an important area of future research. Thus, as use
of belatacept in clinical transplantation is likely to increase fol-
lowing its FDA approval in June 2011, the need to simultaneously
attenuate donor-reactive memory T cell responses by targeting
memory cell-speciﬁc pathways becomes more pressing.
As such, several groups have studied the mechanisms by
which memory T cells escape tolerance induction following cos-
timulatory blockade. Vu et al. (2006) reported that targeting
OX40, but not inducible costimulatory molecule (ICOS), CD70,
or 41BB could synergize with CD28/CD40 blockade to inhibit
rejection mediated by donor-reactive memory cells, but in most
experiments rejection ultimately ensued. In contrast, others have
observed that anti-CD70 could inhibit rejection mediated by
memory cells in mice lacking lymph nodes (Yamada et al., 2005).
Given their homing properties, it seems likely rejection in this
model may be mediated primarily by TEM, although the rela-
tive abundance of donor-reactive cells in the various memory
subsets was not deﬁned. In addition, Valujskikh and colleagues
recently interrogated the role of ICOS (CD278) in the ability of
early graft-inﬁltrating memory T cells to initiate effector functions
associated with graft rejection (Schenk et al., 2009). Their results
revealed that while ICOS was not constitutively expressed on all
memory T cells, its expression was upregulated in situ following
proliferation of memory T cells within the graft itself. Impor-
tantly, blockade of ICOS signaling on memory T cells led to a
signiﬁcant decrease in the early expression of IFN-γ, perforin,
granzyme B, and FasL mRNA within memory T cell-inﬁltrated
allograft (Schenk et al., 2009). In other settings, CD4+ mem-
ory cells escaped anti-CD154 therapy and could provide help for
CD8+ T cell responses, macrophage activation, and anti-donor
antibody production (Chen et al., 2004), and it is tempting to
speculate that theTFH memory subset that expresses TRANCEand
CD30L may have contributed to this CD154 independent rejec-
tion (Crotty, 2011). Furthermore, previous work has shown that
the NFκB inhibitor deoxyspergualin synergized with CD28/CD40
blockade (Adams et al., 2003) to inhibit graft rejection pre-
dominantly mediated by CD8+ TCM. More recent studies have
conﬁrmed these early ﬁndings by demonstrating that reagents
which block proteasome degradation and thereby inhibit NFκB
nuclear translocation also showed efﬁcacy as inhibitors of donor-
reactive memory T cell responses. Speciﬁcally, a recent in vitro
study demonstrated the ability of bortezomib, one such protea-
some inhibitor, to effectively inhibit activation of memory T cells
in vitro (Kim et al., 2009). As an added beneﬁt, bortezomib also
preserved regulatory T cell function in these studies (Kim et al.,
2009).
It is well established that memory T cells mediate graft rejection
by rapidly trafﬁcking into allografts and elaborating inﬂammatory
cytokines that recruit in other innate and adaptive immune cells,
activating the endothelium and epithelium of the graft, and exe-
cuting their cytolytic function. Thus,one potential strategy to limit
their pathogenicity might be to block the ability of memory T cells
to migrate into the transplanted tissue. In 2011, Fairchild and col-
leagues demonstrated that the early inﬁltration of memory T cells
into donor tissue was suppressed following treatment with LFA-
1 antagonists (Setoguchi et al., 2009; Figure 2), and our group
showed that anti-LFA-1 mAb synergized with traditional cos-
timulation blockade in effectively diminishing the donor-reactive
memory T cell response in murine models (Kitchens et al., 2011a).
This synergy was mediated by a decrease in donor-reactive mem-
ory T cell cytokine secretion and cytolytic function in the spleen
and draining lymph nodes in addition to a diminution in antigen-
speciﬁc T cell trafﬁcking into the graft (Kitchens et al., 2011a).
Furthermore, recent translational studies in a non-human pri-
mate model of islet transplantation revealed that a short course of
anti-LFA-1 synergized with belatacept in inhibiting alloislet rejec-
tion (Badell et al., 2010). In addition, efalizumab, initially devel-
oped and FDA approved for the inhibition of autoreactive T cell
responses during psoriasis, was recently tested in phase II clinical
trials in both renal and islet transplantation (Vincenti et al., 2007;
Posselt et al., 2010; Turgeon et al., 2010). These studies assessed
the utility of an efalizumab-based regimen in inhibiting rejection
in recipients of pancreatic islet allografts. Hundred percent of the
patients treatedwith efalizumab in the two islet studiesmaintained
insulin independence for the duration of treatment with the drug
(Posselt et al., 2010; Turgeon et al., 2010). Unfortunately, efal-
izumab was voluntarily withdrawn by the manufacturer in 2009
due to detection of progressive multi-focal leukoencephalopathy
(PML) in patients treated with efalizumab. This rare but poten-
tially fatal JC polyoma-associated disease has thus occurred in
only four of ∼46,000 treated subjects (0.008%; Carson et al.,
2009). While this is clearly a devastating complication, the PML
risk associated with efalizumab is not higher than that associated
with cyclosporine (0.045%), tacrolimus (0.021%), or mycopheno-
late mofetil (0.035%; Neff et al., 2008). Overall, the large number
of treated psoriatic patients combined with relatively rare inci-
dence of side effects suggests that blockade of the LFA-1 pathway
may warrant further investigation for the prophylaxis of trans-
plant rejection (Kitchens et al., 2011b), in order to circumvent
the nephrotoxicity and other side effects associated with current
calcineurin inhibitor-based immunosuppressive regimens.
Other adhesion molecule pathways that have been targeted in
order to overcome the memory T cell barrier include VLA-4, and
adhesion molecule that is not expressed by naïve T cells and that is
upregulated upon activation (Theien et al., 2001).VLA-4 is critical
for T cell entry into peripheral tissues (Kuchroo et al., 1993) and
has blockade of this pathway has been FDA approved for use in
multiple sclerosis (natalizumab; Figure 2). We recently showed in
a murine model of experimental transplantation that treatment
with anti-VLA-4 monoclonal antibodies synergized with costim-
ulatory blockade in inhibiting allograft rejection mediated by
donor-reactivememory T cells (Kitchens et al., 2011a).While anti-
VLA-4 failed to impact donor-reactive memory T cell expansion,
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cytokine secretion, or cytolytic function, it potently inhibited the
ability of donor-reactive memory T cells to trafﬁc into allografts
(Kitchens et al., 2011a). Furthermore, Kirk and colleagues recently
reported the ability of CD2hi TEM cells to mediate CD28 cos-
timulation blockade-resistant rejection, and subsequently targeted
these cells using theCD2 adhesionmolecule blocker LFA-3-Ig (ale-
facept; Weaver et al., 2009; Figure 2). When administered as part
of a regimen consisting also of CTLA-4 Ig (CD28 blockade) and
sirolimus (mTOR inhibition), CD2 adhesion molecule blockade
resulted in renal allograft survival beyond the duration of treat-
ment (>90 days) in ﬁve out of eight non-human primate renal
allograft recipients (Weaver et al., 2009). These results provided the
experimental foundation for the translation of alefacept, which is
currently FDA approved for use in plaque psoriasis, as an adjunct
therapy to be used in combination with CD28 blockers such as
belatacept to inhibit donor-reactive memory T cell responses in
transplantation.
As discussed above, studies have shown that donor-reactive
memory T cells are resistant to the effects of regulation (Yang
et al., 2007). However, recently published data have shown that
the ability of memory T cells to mediate the early recruitment of
neutrophils into transplanted allografts underlies their resistance
to regulation (Jones et al., 2010). Indeed, depletion of neutrophils
from murine transplant recipients resulted in the ability of adop-
tively transferred Treg to suppress the activity of donor-reactive
memory T cells, resulting in long-term graft survival (Jones et al.,
2010). These results indicate that the ability of memory T cells
to activate the innate immune system following transplantation is
an important mechanism by which they facilitate graft rejection,
and suggest that therapeuticmanipulation of these innate immune
components could be utilized in overcoming the memory barrier.
MAINTAINING MEMORY: PROTECTIVE IMMUNITY IN
TRANSPLANTATION
The overall goal of immunomodulatory therapy following trans-
plantation is to inhibit graft rejectionwhilemaintaining protective
immunity. While transplant recipients on current immunosup-
pressive regimens can certainly experience infectious complica-
tions, the fact that patients are not immediately overcome with
opportunistic infections indicates that some degree of protec-
tive immunity is intact, very likely due to the inability of these
immunosuppressive regimens to inhibit immunologic memory.
Thus, strategies designed to inhibit alloreactive memory T cells
must be weighed against the cost of potentially attenuating pro-
tective immunity. For example, as mentioned above, use of LFA-1
and VLA-4 antagonists in autoimmunity (psoriasis and multi-
ple sclerosis, respectively), have resulted in the development of
PML, in a small but signiﬁcant subset of patients (Carson et al.,
2009). Thus, elucidating ways to increase protective immunity
while at the same time inhibit alloreactive T cell responses is criti-
cal to increasing patient health anddecreasingmorbidity following
transplantation.
Given its history as an immunosuppressive and anti-
proliferative agent, surprising observationsweremadewhen inves-
tigators began to interrogate the impact of rapamycin monother-
apy on antigen-speciﬁc T cell responses during the course of viral
or bacterial infection. In two studies published in Nature in 2009,
Araki et al. (2009) and Pearce et al. (2009) demonstrated a para-
doxical immunostimulatory effect of rapamycin on the CD8+
memory T cell response following pathogen infection. Adminis-
tration of a clinically relevant dose (serum levels of 5–25 ng/ml) of
rapamycin during the priming phasewas found to actually increase
the number of virus-speciﬁc memory T cells. Furthermore, when
rapamycin was administered during the contraction phase of the
response alone, the antigen-speciﬁc T cells instead increased in
quality, acquiring amoreTCM-like phenotype (CD62Lhi KLRG-1lo
CD27hi Bcl-2hi) with increased proliferative capacity upon rechal-
lenge. In a series of elegant RNAi knock-down experiments, the
authors went on to show that this enhancement in virus-speciﬁc
responses is a T cell-intrinsic effect (Araki et al., 2009). Thus, in
addition to potential other described effects of mTOR inhibition
on dendritic cells, Treg, or other immune compartments (Thom-
son et al., 2009), these studies point to a direct effect of rapamycin
on CD8+ T cells to enhance both the quantity and quality of
memory T cell differentiation in response to pathogen exposure
in vivo.
These surprising ﬁndings raised the question of whether
clinically relevant dosing of rapamycin monotherapy following
transplantation would also augment graft-speciﬁc CD8+ T cell
responses. Was the enhancing effect of rapamycin being masked
by the presence of other immunosuppressants following trans-
plantation? Or was there a fundamental difference in the effect
of rapamycin on T cells responding to antigen in the context of
a graft versus a pathogen? To address these questions, our group
compared the responses of identicalmonoclonal TCR transgenic T
cells to the same epitope presented by either a graft or a pathogen,
in the presence of rapamycin, and found thatwhile rapamycin aug-
mented the OVA-speciﬁc CD8+ T cell response in the context of a
bacterial infection, it failed to augment the OVA-speciﬁc response
in the setting of a transplant (Ferrer et al., 2010). Additional stud-
ies revealed that rapamycin also inhibited CD8+ T cell responses
to a heterotopic heart transplant or a DST, but augmented CD8+
T cell responses to the transplant-relevant pathogens murine γ-
herpes virus (an EBV homolog) and murine polyoma virus (a
BK/JC homolog). Furthermore, concurrent infection with Lis-
teria did not restore the enhancing effect of rapamycin on the
graft-speciﬁc T cells, suggesting that pathogen-associated inﬂam-
matory signals provided in trans were not sufﬁcient to replicate
the rapamycin-induced augmentation (Ferrer et al., 2010). Since
the TCR afﬁnity, antigen recognized, and dose and timing of
rapamycin administration was identical in both groups, these
data suggested a fundamental difference in the way rapamycin
impacts T cells stimulated in the context of a pathogen vs. the
context of a graft. Understanding the mechanisms underlying this
dichotomous effect of rapamycin on graft- vs. pathogen-speciﬁc T
cell responses might facilitate the inhibition of alloreactive T cell
responses while simultaneously preserving protective immunity.
SUMMARY
Memory T cells represent a yin and yang for transplant recip-
ients, as these cells are intimately involved and in most cases
absolutely required for the maintenance of protective immu-
nity in the face of some degree of immunosuppression, yet from
the evidence presented here they clearly constitute a formidable
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barrier for the successful implementation of tolerance induction
strategies in transplantation. However, based on recent obser-
vations that the precursor frequency of alloreactive memory T
cells is highly donor-speciﬁc, determination of quantity (and
likely quality) of donor-speciﬁc T cell memory for a particular
donor/recipient combination would allow stratiﬁcation of relative
risk of alloreactive memory T cell mediated rejection, or con-
versely, likelihood of successful establishment of tolerance. This
strategy would allow for circumvention of the memory barrier in
certain patients, while ongoing research is aimed at designing new
strategies to overcome it without critically impairing protective
immunity.
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